Hypercortisolism

More than three-quarters of adults with Cushing’s disease assigned osilodrostat had a normalized mean urinary free cortisol level at 12 weeks and maintained a normal level at 36 weeks, according to data from the LINC 4 phase 3 trial.

The FDA approved the steroidogenesis inhibitor levoketoconazole for adults with Cushing’s syndrome for whom surgery is not an option or has not been curative, according to an industry press release.

Central hypothyroidism is prevalent in about 1 in 2 adults with Cushing’s syndrome, and thyroid function can be restored after curative surgery for most patients, according to study findings.

Adults with Cushing’s disease who took the cortisol synthesis inhibitor osilodrostat were more likely to sustain a normal mean urinary free cortisol level vs. placebo, according to press release from Recordati Rare Diseases.

More than a century has passed since neurosurgeon and pathologist Harvey Cushing described the disease that would eventually bear his name, but only recently have several key discoveries offered patients with the condition real hope for a cure.

Use of the dopamine agonist cabergoline during conventional fractionated radiotherapy to treat Cushing’s disease may be associated with a higher disease recurrence rate after an initial remission, according to findings published in Clinical Endocrinology.

For patients with persistent or recurring Cushing’s disease, monthly pasireotide therapy was safe and effective, leading to normal urinary free cortisol levels in 47% of patients after 2 years, according to findings published in Clinical Endocrinology.